Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
We have launched a new survey to understand how people with severe asthma feel about the toolsused for asthma. These tools helpdoctors and nurses tocheck if a treatment is working for an individual patient.
This anonymous survey is part of a European project called 3TR. In this project we would like to understand patients’ views to choose the best tools for severe asthma and improve the care of patients across Europe.
Who can take part?
We would like to invite you to participate if:
If you have severe asthma and are a parent or carer of someone with severe asthma, please complete the survey twice, once for yourself and once for your child or the person you care for.
The survey and news article are available in 14 languages:
Help us reach as many people as possible by sharing the survey link with anyone who may be interested in giving their views. The survey will take about 15 minutes to complete.
Who developed the survey?
This survey was developed by a group of patient representatives, healthcare professionals and researchers from the 3TR project, European Lung Foundation and European Federation of Allergy and Airways Diseases Patients’ Associations.
The 3TR project aims to help us choose the right treatment for the right patient with severe asthma. You can find out more about the 3TR project here.
Contact
If you have any questions, please email Kate Khaleva: e.khaleva@soton.ac.uk
Thank you very much for helping us with this work.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434 (3TR). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Content of this publication reflects only the author’s view and the JU is not responsible for any use that may be made of the information it contains.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79